Effect analysis of bevacizumab combined with albumin-bound paclitaxel and nedaplatin in patients with recurrent cervical cancer
Objective To explore the clinical effect of bevacizumab combined with albumin-bound paclitaxel and nedaplatin in the treatment of patients with recurrent cervical cancer.Methods 40 patients with recurrent cervical cancer were selected as the study objects,and were divided into control group and study group,with 20 patients in each group.The control group received combination chemotherapy with bevacizumab,paclitaxel and cisplatin,while the study group received combination chemotherapy with bevacizumab,albumin-bound paclitaxel and nedaplatin.The clinical efficacy,tumor markers before and after treatment and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the study group was 80.00％,which was higher than that of the control group 50.00％(P＜0.05).After treatment,the CEA and SCC indexes of the study group were lower than those of the control group(P＜0.05).The incidence of adverse reactions in the study group(10.00％)was lower than that in the control group(40.00％)(P＜0.05).Conclusion The combination of bevacizumab with albumin-bound paclitaxel and nedaplatin in the treatment of patients with recurrent cervical cancer has a positive effect on the condition,effectively improves the tumor markers,and has high drug safety and clinical application value.
BevacizumabAlbumin-bound paclitaxelNedaplatinRecurrenceCervical cancer
NETL
NSTL
万方数据
